In:
Endocrine, Metabolic & Immune Disorders - Drug Targets, Bentham Science Publishers Ltd., Vol. 21, No. 3 ( 2021-03), p. 397-406
Abstract:
Immune thrombocytopenia (ITP) is a common bleeding disorder
in childhood. The management of ITP in children is controversial, requiring personalized assessment of patients and therapeutic choices. Thrombopoietin receptor agonists (TPO-RAs), eltrombopag
and romiplostim, have been shown to be safe and effective for the treatment of pediatric ITP. The aim of our research is to define the role of thrombopoietin receptor agonists in the management of pediatric
ITP. Methods: This review focuses on the use of TPO-RAs in pediatric ITP, in randomized trials and in
clinical routine, highlighting their key role in the management of the disease. Results: Eltrombopag and romiplostim appear effective treatment options for children with ITP. Several
clinical studies have assessed that the use of TPO-RAs increases platelet count, decreases bleeding symptoms and improves health-related quality of life. Moreover, TPO-RAs are well tolerated with
minor side effects. Conclusion: Although long term efficacy and safety of TPO-RAs still require further investigations,
their use is gradually expanding in the clinical practice of children with ITP.
Type of Medium:
Online Resource
ISSN:
1871-5303
DOI:
10.2174/1871530320666200531142244
Language:
English
Publisher:
Bentham Science Publishers Ltd.
Publication Date:
2021
